Výsledky vyhledávání - "Hans Berkhof"

Warranty period of coronary computed tomography angiography and [15O]H2O positron emission tomography in symptomatic patients

Autor: Ruurt Jukema, Teemu Maaniitty, Pepijn van Diemen, Hans Berkhof, Pieter G Raijmakers, Ralf Sprengers, R Nils Planken, Paul Knaapen, Antti Saraste, Ibrahim Danad, Juhani Knuuti

Publikováno v: European heart journal. Cardiovascular Imaging. Oxford University Press
European heart journal. Cardiovascular Imaging, 24(3), 304-311
Jukema, R, Maaniitty, T, van Diemen, P, Berkhof, H, Raijmakers, P G, Sprengers, R, Planken, R N, Knaapen, P, Saraste, A, Danad, I & Knuuti, J 2023, ' Warranty period of coronary computed tomography angiography and [15O]H2O positron emission tomography in symptomatic patients ', European heart journal. Cardiovascular Imaging, vol. 24, no. 3, pp. 304-311 . https://doi.org/10.1093/ehjci/jeac258

AimsData on the warranty period of coronary computed tomography angiography (CTA) and combined coronary CTA/positron emission tomography (PET) are scarce. The present study aimed to determine the event-free (warranty) period after coronary CTA and th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9260a7de88f7d298e56c1788504d09ab
https://pure.amc.nl/en/publications/warranty-period-of-coronary-computed-tomography-angiography-and-15oh2o-positron-emission-tomography-in-symptomatic-patients(81c35941-4b9c-4667-9c81-0cc7348463bc).html

Zobrazit plný text záznamu

DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial: argument for maximum screening interval of 2years

Autor: Anne M. Uyterlinde, Clemens F.M. Prinsen, Harry J.M. Groen, Susanne E van der Meer, Anne S. Bolijn, Hans Berkhof, Harry J. de Koning, A. Jasmijn Hubers, Renske D.M. Steenbergen, Birgit I. Witte, Mandy Wouters, Daniëlle A.M. Heideman, Peter J.F. Snijders, Erik Thunnissen, Sylvia Duin, Egbert F. Smit

Publikováno v: Journal of Clinical Pathology, 70(3), 250-254. BMJ Publishing Group
Journal of Clinical Pathology, 70(3), 250-254. BMJ PUBLISHING GROUP
Journal of Clinical Pathology. BMJ Publishing Group
Hubers, A J, Heideman, D A M, Duin, S, Witte, B I, de Koning, H J, Groen, H J M, Prinsen, C F M, Bolijn, A S, Wouters, M, van der Meer, S E, Steenbergen, R D M, Snijders, P J F, Uyterlinde, A, Berkhof, H, Smit, E F & Thunnissen, E 2016, ' DNA hypermethylation analysis in sputum of asymptomatic subjects at risk for lung cancer participating in the NELSON trial : argument for maximum screening interval of 2 years ', Journal of Clinical Pathology . https://doi.org/10.1136/jclinpath-2016-203734

AIMS: Lung cancer is the major contributor to cancer mortality due to metastasised disease at time of presentation. The current study investigated DNA hypermethylation of biomarkers RASSF1A, APC, cytoglobin, 3OST2, FAM19A4, PHACTR3 and PRDM14 in sput

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7729a9a7bca4fb579443bbf94ae1e493
https://doi.org/10.1136/jclinpath-2016-203734

Zobrazit plný text záznamu

Additional Value of CSF Amyloid-beta(40) Levels in the Differentiation between FTLD and Control Subjects

Autor: Hans Berkhof, Wiesje M. van der Flier, Yolande A.L. Pijnenburg, Maartje I. Kester, Harry Twaalfhoven, Nicolaas A. Verwey, Marinus A. Blankenstein, Philip Scheltens and, Robert Veerhuis

Publikováno v: Journal of Alzheimer's Disease, 20(2), 445-452. IOS Press
Verwey, N A, Kester, M I, van der Flier, W M, Veerhuis, R, Berkhof, J, Twaalfhoven, H A M, Blankenstein, M A, Scheltens, P & Pijnenburg, Y A L 2010, ' Additional Value of CSF Amyloid-beta(40) Levels in the Differentiation between FTLD and Control Subjects ', Journal of Alzheimer's Disease, vol. 20, no. 2, pp. 445-452 . https://doi.org/10.3233/JAD-2010-1392

To determine the additional value of cerebrospinal fluid (CSF)amyloid-beta1-40 (Abeta40) next to amyloid-beta1-42 (beta42), total tau (Tau), and tau phosphorylated at threonine-181 (pTau) to distinguish patients with frontotemporal lobar degeneration

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd96fcca1e50f1498b71049a98f740bc
https://doi.org/10.3233/jad-2010-1392

Zobrazit plný text záznamu

Validation of high-risk HPV tests for primary cervical screening

Autor: D.A.M. Heideman, Hans Berkhof, Chris J.L.M. Meijer, Albertus T. Hesselink, Peter J.F. Snijders

Publikováno v: Meijer, C J L M, Berkhof, J, Heideman, D A M, Hesselink, A T & Snijders, P J F 2009, ' Validation of high-risk HPV tests for primary cervical screening ', Journal of Clinical Virology, vol. 46 Suppl 3, pp. S1-S4 . https://doi.org/10.1016/s1386-6532(09)00540-x, https://doi.org/10.1016/S1386-6532(09)00540-X
Journal of Clinical Virology, 46 Suppl 3, S1-S4. Elsevier

From a clinical point of view, testing for a broad spectrum of high-risk human papillomavirus (hrHPV) is only useful when a positive hrHPV test result is informative about the presence of high-grade cervical intraepithelial neoplasia or cervical canc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88ca654e03bc5e2fd5a09ccb4968a7d3
https://doi.org/10.1016/s1386-6532(09)00540-x

Zobrazit plný text záznamu

Four-year follow-up of poly-L-lactic Acid cages for lumbar interbody fusion in goats

Autor: Paul I. J. M. Wuisman, Theo H. Smit, Martijn van Dijk, Hans Berkhof, Paul J. van Diest, Elisabeth H. Burger

Publikováno v: van Dijk, M, van Diest, P J, Smit, T H, Berkhof, H, Burger, E H & Wuisman, P I J M 2005, ' Four-year follow-up of poly-L-lactic Acid cages for lumbar interbody fusion in goats ', Journal of long-term effects of medical implants, vol. 15, no. 2, pp. 125-38 . https://doi.org/10.1615/jlongtermeffmedimplants.v15.i2.20
Journal of long-term effects of medical implants, 15(2), 125-38. Begell House Inc.

BACKGROUND: New applications of bioabsorbable polymer implants demand for histologic evaluation because a host tissue response is elicited and late complications after polymer implantation have been reported. Furthermore, in load-bearing regions an a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff22c3a00ab50e6a47fd353169e75dcf
https://doi.org/10.1615/jlongtermeffmedimplants.v15.i2.20

Zobrazit plný text záznamu

Phase II Study on Bortezomib (BTZ) in Multiple Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (rALL): High Response Rate with a Modestly Intensive Regimen Including BTZ, Not Related to Pharmacokinetics

Publikováno v: Blood. 126:2501-2501

BTZ is a proteasome inhibitor and could improve the poor prognosis of rALL (Messinger 2012). We developed a European phase II study in pediatric rALL, in which patients were randomised for 'early' or 'late' BTZ, in compliance with the Declaration of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8c629291078140fc7ee4c84be235125e
https://doi.org/10.1182/blood.v126.23.2501.2501

Zobrazit plný text záznamu

Prevention of cervical cancer: Where immunology meets diagnostics

Autor: Peter J.F. Snijders, Hans Berkhof, Chris J.L.M. Meijer, Daniëlle A.M. Heideman

Publikováno v: Meijer, C J L M, Heideman, D A M, Berkhof, J & Snijders, P J F 2009, ' Prevention of cervical cancer : where immunology meets diagnostics ', Immunology Letters, vol. 122, no. 2, pp. 126-7 . https://doi.org/10.1016/j.imlet.2008.11.011
Immunology Letters, 122(2), 126-7. Elsevier

Based on the insight that cervical cancer is caused by high-risk human papillomavirus (hrHPV) types, two new directions of cervical cancer prevention have emerged: primary prevention by prophylactic vaccination against hrHPV types 16 and 18, and seco

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1a112b043b4adb0ba4e836ed38383b9
https://doi.org/10.1016/j.imlet.2008.11.011

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání